Recce patent extends Vietnam protection to 2041 - ICYMI

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) earlier this week strengthened its intellectual property position in Southeast Asia after securing a Vietnamese patent covering the manufacture and use of its RECCE® 327 and RECCE® 529 synthetic anti-infective candidates. The Family 4 patent, granted by the Intellectual Property Office of Vietnam, provides protection until 2041 and represents the eighth patent secured by the company within this patent family. Chief executive James Graham said the award was significant because it extended Recce Pharmaceuticals’ potential market monopoly in Vietnam to 2041. He explained that the claims covered the preparation and manufacture of R327 and R529, as well as their use against bacterial, viral and other infectious diseases. Graham described the patent as “broad” and “all-encompassing”, with potential applications including acute bacterial skin and skin structure infections, diabetic foot ulcer infections and burn wound infections. Vietnam was strategically important because it formed part of the ASEAN group of countries, Graham said. He pointed to the prevalence of diabetes in the region and the associated risk of infected diabetic foot ulcers, while also highlighting high levels of resistance to existing antibiotics and the absence of an established standard of care in some markets. The company’s Indonesian Phase 3 program represented one of the most important near-term catalysts.